Filter your search
The medical device industry, heavily regulated in most nations of the world, has unique challenges and opportunities. Medical device companies must make constant research and development investments to produce the innovations that drive market success. Despite challenges medical device companies are facing, an unexpectedly enlarging elderly population worldwide benefits tremendously from medical devices. Medical devices are among the first priority of emerging market nations as their economies expand and healthcare expenditure increases. Consequently, there is a growing number of medical device companies, as well as investors in the field. Revenue trends at major medical device companies have changed, and Kalorama Information’s market research reports provide up-to-date market forecasts that follow the emerging trends influencing medical device companies. Our research keeps you updated on the host of mergers and acquisitions transpiring in the medical device market as companies seek to expand their manufacturing operations. Kalorama’s collection of reports on the medical device market opportunity covers the wound care, drug delivery, equipment, and surgical market segments, featuring reports on the wound care market as a whole, wearable medical devices, and remote patient monitoring systems, among many other topics.
Wound Care
Drug Delivery
Equipment
Surgical
- $995.00 – $2,992.00According to the Pharmaceutical Research and Manufacturers of America (PhRMA) more than 1,000 drugs are in various stages of development. Similarly, breakthroughs in the medical device arena such as coronary stents, implantable defibrillators, and minimally invasive bypass surgery and advances in DNA-based tests and other advanced diagnostics are detecting cancer and other diseases earlier when […]June 1, 2003$1,875.00 – $3,750.00Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the […]April 1, 2003$371.00 – $742.00The market for diabetes care products covers the spectrum of clinical medicine, including diagnostics, biologics, and drugs. Several areas have strong growth potential and others, such as drugs to treat complications, represent large underserved markets for drugs primarily marketed to other populations. Segmentation of patient populations in novel ways, such as diabetic candidates for cardiovascular […]April 1, 2003$371.00 – $742.00The market for diabetes care products covers the spectrum of clinical medicine, including diagnostics, biologics, and drugs. Several areas have strong growth potential and others, such as drugs to treat complications, represent large underserved markets for drugs primarily marketed to other populations. Segmentation of patient populations in novel ways, such as diabetic candidates for cardiovascular […]April 1, 2003$371.00 – $742.00Diabetes monitoring and therapeutics to manage the disease and its complications continues to be an attractive market for many manufacturers. However, the factors that affect the potential of diabetes markets—including population demographics and the attitude of healthcare policy makers and clinicians—can seem like shifting sands from one country to the next. That’s why Kalorama is […]March 1, 2003